Wake Research - Clinical Research Center of Nevada
Welcome,         Profile    Billing    Logout  
 5 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Duara, Ranjan
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26
TRC-PAD, NCT04004767: Program: In-Clinic Trial-Ready Cohort

Completed
N/A
220
US
University of Southern California, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute, Alzheimer's Clinical Trials Consortium, Brigham and Women's Hospital, Cleveland Clinic Lou Ruvo Center for Brain Health
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
04/24
04/24
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
850
Europe, US, RoW
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/25
05/25
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Allen, Lawrence
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
Farrow, Simon
Polaris-AD, NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease

Recruiting
3
1150
Europe, US, RoW
AR1001, Placebo
AriBio Co., Ltd.
Alzheimer Disease
12/25
12/27
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
Jayaraman, Vijay
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Steljes, Darlene
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Kill, Amy
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults

Completed
2
797
NA
ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline
AEON Biopharma, Inc., PPD
Migraine
06/24
08/24
Janda, Paul
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Enrolling by invitation
3
285
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/25
01/26

Download Options